SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease

Occupational and Environmental Medicine

Volumn 68, Issue 10, 2011, Pages 759-764

  Tooker, Brian C ^a   Bowler, R P ^b   Orcutt, J M ^b   Maier, L A ^a,b   Christensen, H M ^a   Newman, L S ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM; BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; PLASMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ARTICLE; BERYLLIOSIS; BERYLLIUM LYMPHOCYTE PROLIFERATION TEST; BLOOD SAMPLING; BRONCHOSCOPY; CHRONIC DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ETHNICITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; INVASIVE PROCEDURE; LABORATORY TEST; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SENSITIZATION; SEX DIFFERENCE; SMOKING; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TOTAL LUNG CAPACITY;

BERYLLIOSIS; BERYLLIUM; BIOLOGICAL MARKERS; BLOOD PROTEINS; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 80052940953     PISSN: 13510711     EISSN: 14707926     Source Type: Journal    
DOI: 10.1136/oem.2010.058966     Document Type: Article

References (39)

1. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85. (Pubitemid 38443834)
2. Harezlak J, Wu MC, Wang M, et al. Biomarker discovery for arsenic exposure using functional data. Analysis and feature learning of mass spectrometry proteomic data. J Proteome Res 2008;7:217-24. (Pubitemid 351171134)
3. Zhai R, Sh S, Lu X, et al. Proteomic profiling in the sera of workers occupationally exposed to arsenic and lead: identification of potential biomarkers. Biometals 2005;18:603-13. (Pubitemid 43030282)
4. Toraason M, Albertini R, Bayard S, et al. Applying new biotechnologies to the study of occupational cancerea workshop summary. Environ Health Perspect 2004;112:413-16. (Pubitemid 38404550)
5. Zhang X, Jin M, Wu H, et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 2008;74:799-807.
6. Zinkin NT, Grall F, Bhaskar K, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008;14:470-7. (Pubitemid 351226115)
7. Bons JA, Drent M, Bouwman FG, et al. Potential biomarkers for diagnosis of sarcoidosis using proteomics in serum. Respir Med 2007;101:1687-95. (Pubitemid 46930713)
8. Akashi T, Nishimura Y, Wakatabe R, et al. Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer. Biochem Biophys Res Commun 2007;352:514-21. (Pubitemid 44841964)
9. Lakhan SE. Schizophrenia proteomics: biomarkers on the path to laboratory medicine? Diagn Pathol 2006;1:11.
10. Tomosugi N. [Discovery of disease biomarkers by ProteinChip system; clinical proteomics as noninvasive diagnostic tool]. Rinsho Byori 2004;52:973-9.
11. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304. (Pubitemid 34809839)
12. Infante PF, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet 2004;363:415-16. (Pubitemid 38210056)
13. Kelleher PC, Martyny JW, Mroz MM, et al. Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med 2001;43:238-49. (Pubitemid 32238503)
14. Maier LA, Martyny JW, Liang J, et al. Recent chronic beryllium disease in residents surrounding a beryllium facility. Am J Respir Crit Care Med 2008;177:1012-17. (Pubitemid 351717596)
15. Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992;145:1212-14.
16. Newman LS, Mroz MM, Balkissoon R, et al. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005;171:54-60. (Pubitemid 40051695)
17. Kreiss K, Newman LS, Mroz MM, et al. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989;31:603-8. (Pubitemid 19179743)
18. Newman LS, Kreiss K, King TE, et al. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 1989;139:1479-86. (Pubitemid 19155510)
19. Bost TW, Riches DW, Schumacher B, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta. Am J Respir Cell Mol Biol 1994;10:506-13.
20. Maier LA, Sawyer RT, Tinkle SS, et al. IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis. Eur Respir J 2001;17:403-15. (Pubitemid 32600608)
21. Tinkle SS, Kittle LA, Newman LS. Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease. J Immunol 1999;63:2747-53. (Pubitemid 29399201)
22. Tinkle SS, Kittle LA, Schumacher BA, et al. Beryllium induces IL-2 and IFN-gamma in berylliosis. J Immunol 1997;158:518-26. (Pubitemid 127483896)
23. Tinkle SS, Newman LS. Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease. Am J Respir Crit Care Med 1997;156:1884-91. (Pubitemid 28011797)
24. Cadieux PA, Beiko DT, Watterson JD, et al. Surface-enhanced laser desorption/ ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. J Clin Lab Anal 2004;18:170-5. (Pubitemid 38585794)
25. Lin Z, Jenson SD, Lim MS, et al. Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma. Mod Pathol 2004;17:670-8. (Pubitemid 38715489)
26. Ryu OH, Atkinson JC, Hoehn GT, et al. Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology (Oxford) 2006;45:1077-86. (Pubitemid 44542092)
27. Schaub S, Wilkins J, Weiler T, et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65:323-32. (Pubitemid 38037520)
28. Schweigert FJ, Wirth K, Raila J. Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci 2004;2:5.
29. Breiman L, Friedman JH, Olshen RA, et al. Classification and Regression Trees. New York: Chapman and Hall, 1984.
30. Liu P, Hwang JT. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis. Bioinformatics 2007;23:739-46. (Pubitemid 46554726)
31. Zolg JW, Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol Cell Proteomics 2004;3:345-54. (Pubitemid 38702088)
32. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6. (Pubitemid 38351297)
33. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207. (Pubitemid 36362757)
34. Gillette MA, Mani DR, Carr SA. Place of pattern in proteomic biomarker discovery. J Proteome Res 2005;4:1143-54. (Pubitemid 41208673)
35. Marshall J, Kupchak P, Zhu W, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003;2:361-72. (Pubitemid 36988415)
36. Banks RE, Stanley AJ, Cairns DA, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ ionization mass spectrometry. Clin Chem 2005;51:1637-49. (Pubitemid 41233099)
37. Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003;63:6971-83. (Pubitemid 37322984)
38. Frome EL, Newman LS, Cragle DL, et al. Identification of an abnormal beryllium lymphocyte proliferation test. Toxicology 2003;183:39-56. (Pubitemid 36005388)
39. Stange AW, Furman FJ, Hilmas DE. The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance. Am J Ind Med 2004;46:453-62. (Pubitemid 39507658)